R
Resalis Therapeutics
Biopharma company focused on the development of oligonucleotide anti-sense therapies to treat metabolic disorders, including NAFLD/MAFLD/NASH, obesity, and cancer
About Resalis Therapeutics
Resalis Therapeutics is a biotechnology startup that operates in the healthcare sector, specifically focusing on the development of treatments for metabolic diseases such as obesity and fatty liver disease. The company's innovative approach targets a master regulator of multiple pathways that underlie these diseases, using a non-coding RNA drug modality. In simpler terms, they are developing drugs that can interact with our genetic material to regulate the body's metabolism and combat these diseases.
Their lead program, RES-010, is being developed as a safe and convenient treatment that not only aids in weight loss but also reduces hepatic steatosis, a condition characterized by the buildup of fat in the liver. The company's business model revolves around the research, development, and eventual commercialization of this drug. They aim to generate revenue through the sale of RES-010 once it has been approved for use in the market.
Resalis Therapeutics serves a broad client base that includes individuals suffering from obesity and fatty liver disease. Given the increasing prevalence of these conditions globally, the market potential for their product is significant. The company is currently in the preclinical stage, gathering robust evidence to support the effectiveness of RES-010. They plan to rapidly progress to clinical trials, testing the drug on a range of metabolic disorders.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Oct 2024 | $0 | — | Sanofi Ventures | ↗ |
| SERIES A✓Equity / VC | Jan 2024 | $11M | $44M | Claris Ventures · Sunstone Life Science Ventures | ↗ |
Growth signals
Latest recorded traffic for Resalis Therapeutics is 310 monthly website visits, up 210% over the last three months. Resalis Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Resalis Therapeutics in the Turin ecosystem
The Resalis Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Claris Ventures
Italian Angels for Growth
Investors' club
Series A2 investors entered at this stage
Sunstone Life Science Ventures
Sanofi Ventures
Other known investors2 additional known investors
Aalborg University
Silvia Pugi
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Resalis Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Resalis Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









